We examined the association of cardiovascular health at younger ages with the proportion of life lived free of morbidity, the cumulative burden of morbidity, and average healthcare costs at older ages.
T he burden of cardiovascular disease (CVD) is expected to increase dramatically over the next several decades, with estimates that 40.5% of the US population will be living with CVD by 2030. 1 Primordial prevention (ie, preventing the development of risk factors, not just preventing disease once risk develops) may represent the most effective means of reducing the burden of CVD 2 and was a key concept in guiding the development of national goals to improve the cardiovascular health of the United Sates, including the American Heart Association's 2020 Impact Goals 3 and the Healthy People 2010 Goals. 4 Favorable cardiovascular health in middle age has consistently been associated with decreased all-cause and cardiovascular mortality later in life, resulting in 5.8 to 9.5 additional years of life. 5 Beyond mortality, favorable cardiovascular health results in even more dramatic reductions in the risk for incident CVD events 6, 7 and other major chronic diseases later in life. 8, 9 To date, little is known about how favorable cardiovascular health affects the overall burden and severity of morbidity in older age. The goal of this study was to determine whether favorable cardiovascular health is associated with longer, healthier lives or whether it simply extends life at the cost of increasing morbidity and cost.
METHODS Sample
The CHA study (Chicago Heart Association Detection Project in Industry) is a longitudinal prospective investigation of 39 522 men and women (Asian, black, Hispanic, white, and other) 18 to 74 years of age at baseline in 1967 to 1973 and employed in the Chicago area. 10 Data were collected on demographic, medical history, and medical treatment by questionnaire; measurement of height, weight, heart rate, casual blood pressure and ECG; and collection of blood for measurement of serum total cholesterol and plasma glucose 1 hour after a 50-g oral glucose load. The study was approved by the institutional review board at Northwestern University, and all participants signed an informed consent.
The CHA cohort has been followed for >40 years since baseline through personal contact, National Death Index data, and linked Medicare files from 1984 through 2010. In this study, we included CHA participants who were ≥65 years of age during follow-up and enrolled in Medicare fee for service. We excluded individuals missing baseline risk factor levels or demographic information. The final study cohort for this analysis included 25 804 individuals who became ≥65 years of age by 2010, representing 65% of all original CHA participants ( Figure I in the online-only Data Supplement).
Favorable Cardiovascular Health
Favorable cardiovascular health was defined as having favorable levels of all major cardiovascular risk factors, including blood pressure, cholesterol, diabetes mellitus, body mass index, and smoking (Table 1) . Individuals without a favorable cardiovascular health profile were further classified into 3 mutually exclusive categories based on their risk factor levels: 0 high risk factors but ≥1 elevated above favorable levels, 1 high major risk factor, and ≥2 high major risk factors. Favorable, elevated, and high risk factor levels are defined in Table 1 according to appropriate clinical guidelines.
Morbidity Scores
All-cause morbidity was defined with the Gagne comorbidity score, a well-validated comorbidity score designed specifically for use with administrative (ie, Centers for Medicare & Medicaid Services [CMS]) data and based on International Classification of Diseases, Ninth Revision discharge diagnosis codes. 11 The score includes the following conditions (weights): metastatic cancer (5), congestive heart failure (2), dementia (2), renal failure (2), weight loss (2), hemiplegia, alcohol abuse, any tumor, cardiac arrhythmias, chronic pulmonary disease, coagulopathy, complicated diabetes mellitus, deficiency anemias, fluid and electrolyte disorders, liver disease, peripheral vascular disorder, psychosis, pulmonary circulation disorders, HIV/AIDS (−1), and hypertension (−1). A higher score represents a greater comorbidity burden.
Cardiovascular morbidity was quantified with a CVD comorbidity score, defined by the sum of the presence of 4 CVDs, including coronary heart disease (including myocardial What Are the Clinical Implications?
• Our findings highlight the importance of prevention.
• At the individual level, living a longer and healthier life free of major morbidity can provide strong motivation to maintain and improve cardiovascular health across the life span.
• At the population and healthcare system levels, these findings directly support the need to improve prevention efforts and to target them earlier in life, before the development of adverse risk factor levels (ie, primordial prevention).
• Our data suggest that the resultant reductions in morbidity could translate to large savings in healthcare spending at the national level.
infarction), peripheral vascular disease, cerebrovascular disease, and chronic heart failure. The score ranged from 0 to 4, with increasing score reflecting a greater burden of CVD. Scores were examined longitudinally over time for each CHA participant included in these analyses. Comorbid conditions were included in the score if they were present in any of the top 6 discharge diagnoses codes (International Classification of Diseases, Ninth Revision codes) for any of the participant's inpatient hospitalization or outpatient visit claims. The score was calculated for each participant at each year of age from 65 (or age in 1984, whichever is older) until death or the end of follow-up. If participants were not hospitalized or seen as an outpatient during any specific year, they were assigned a score of 0 for that year of age. Significant comorbidity was defined as a score of ≥1 consistent with having an intermediate to high risk of 1-year mortality.
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Healthcare Costs
We examined differences in average annual costs using Medicare claims for each of our 4 cardiovascular health strata. Average annual costs were calculated as the total cumulative cost divided by the years of follow-up. Cost data from CMS data reflect charges for medical services obtained as a result of an inpatient hospital stay; outpatient services obtained at a hospital, at a clinic, or in a physician's office; and fees for physician services. Because Medicare is considered the primary payer by other insurers, claims for individuals with additional coverage are still sent to CMS; thus, Medicare claims data provide a nearly complete documentation of hospital, home health agency, hospice, skilled nursing facility, and physician charges. Additional details are given in the online-only Data Supplement.
Statistical Analyses
In bivariate analyses, we examined demographic characteristics of included CHA participants stratified by their burden of cardiovascular risk factors. We used χ 2 tests and ANOVA to compare categorical and continuous characteristics of participants across the 4 risk factor strata, respectively. To examine the age at incidence of major morbidity, we restricted these models to the ≈70% (n=17 939 for all-cause morbidity and 18 714 for cardiovascular morbidity) of CHA participants for whom we had Medicare follow-up starting at age 65 and who had morbidity scores of 0 at age 65. We used a penalized spline model to obtain a nonparametric estimate of the mean comorbidity score over ages 65 to 90 for each stratum of cardiovascular health profile. 12 A random intercept was included in the model to take into account the within-individual correlation. We examined the times to 4 events: (1) time to morbidity score reaching 1 or death, (2) time to morbidity score reaching 2 or death, (3) time to morbidity score reaching 3 or death, and (4) time to death. Because censoring precludes estimation of these mean survival times, we used the Irwin restricted mean, which is the mean of the survival time restricted to a given time point and is mathematically equivalent to the area under the survival curve up to the selected restriction time point. 13 We then used the difference among the restricted mean survival times for these 4 events to examine the proportion of life lived with morbidity scores of 1, 2, and ≥3. Analyses were done overall and stratified by sex, morbidity status, and baseline age category (≤ 40, 41-50, >50 years).
Because medical costs are right skewed and heteroscedastic, we used quantile regression to model the median and third quartile (75%) medical costs instead of the mean to determine whether individuals with favorable cardiovascular health profile have lower cumulative and average annual healthcare costs across the range of medical costs. SAS Proc Quantreg was used to fit the model. All models were adjusted for age, sex, race, education, and whether the individual died during followup (in overall analyses). We also performed a subgroup analysis among participants who had died during follow-up.
RESULTS
Baseline Characteristics
This study included 25 804 CHA participants, of whom 5.6% had favorable levels of all major cardiovascular risk factors at baseline, 19.0% had ≥1 elevated but no high levels, 40.3% had 1 high level, and 35.1% had ≥2 high cardiovascular risk factor levels ( Table 2) . Individuals with favorable cardiovascular health at baseline were younger, were more likely to be female, and had a higher education level.
Cardiovascular Health at Younger Ages and Morbidity at Older Ages
With poorer cardiovascular health at baseline, both allcause and cardiovascular morbidity scores were higher at age 65 and remained higher through age 90 (Figures II and III in the online-only Data Supplement). When examining the cumulative burden of morbidity and the incidence of major morbidity, we restricted our analyses to the 17 939 participants with an allcause morbidity score of 0 at age 65 and 18 714 participants with a cardiovascular morbidity score of 0 at age 65. Morbidity scores increased linearly with age ( Figure 1 and Figures IV and V in the online-only Data Supplement), and individuals with a poorer cardiovascular health at younger ages experienced higher allcause and cardiovascular morbidity scores from ages 65 through 90. The cumulative morbidity as defined by the area under the morbidity curve (which is equivalent to the sum of morbidity scores from ages 65 through 90) was lower for those with all favorable risk factor levels (P<0.05; Table I in the online-only Data Supplement). Figure 1 . Mean follow-up morbidity score by cardiovascular (CV) risk factor level among those with morbidity score of 0 at age 65 years.
A, All-cause morbidity. B, Cardiovascular morbidity.
Morbidity-Free Survival and Compression of Morbidity
Being in favorable cardiovascular health significantly delayed the incidence of major all-cause and cardiovascular morbidity by an average of 4.5 and 6.9 years, respectively, compared with individuals with ≥2 high risk factors (Table I in the online-only Data Supplement and Figure 2 ). In addition to morbidity incidence, on average, individuals in favorable cardiovascular health lived 3.9 years longer than those with ≥2 high risk factor levels. Similar patterns were seen for women and men (Figures VI and VII in the online-only Data Supplement). Baseline cardiovascular health was associated with a significant relative compression of both all-cause and cardiovascular morbidity. The proportion of later life (life after age 65 years) lived with any all-cause morbidity ranged from 39% for those with favorable cardiovascular health at younger ages to 50% for those with ≥2 high risk factors and from 23% to 43% for cardiovascular morbidity. We observed minimal absolute compression of all-cause morbidity. Regardless of risk factor strata, individuals lived on average 10 years with some all-cause morbidity (Table II in the online-only Data Supplement); however, the overall burden of major comorbidities that individuals experienced during these 10 years was lower for those people who were in favorable cardiovascular health at baseline, as evidenced by the shorter duration of extremely high levels of morbidity (score ≥3; P<0.05 compared with individuals in favorable cardiovascular health). Compression of the absolute number of years lived with morbidity was stronger among men, who lived almost 5 years longer without morbidity and 1 year less with morbidity ( Figure VIA in the online-only Data Supplement).
In contrast to all-cause morbidity, cardiovascular health at younger ages was significantly associated with both absolute and relative compression of cardiovascular morbidity at older ages (Figure 2 and Tables II and III in the online-only Data Supplement). Similar to all-cause morbidity, men experienced a greater benefit in terms of the compression of morbidity than women (Table II in 
Medicare Costs
The differences in average and cumulative morbidity observed across cardiovascular health strata defined at younger ages translated to lower Medicare costs after age 65 among individuals in favorable cardiovascular health compared with those with ≥2 high risk factors (Table 3) . Overall, there was a significant trend for increased average annual costs and cumulative costs with greater risk factor burden (P for trend <0.001). When the analysis was restricted to individuals who died during follow-up, patterns were consistent, although there was some attenuation of the P values as a result of reductions in sample size.
Sensitivity Analyses
Findings were consistent when limited to CHA participants who died during follow-up ( Figure VIII and Table V in the online-only Data Supplement). After stratification by baseline age categories, similar patterns in the incidence of morbidity and compression of morbidity across all 3 baseline age groups were observed ( Figure  IX -XI in the online-only Data Supplement). The only difference was in the oldest age group (baseline age >50 in 1967-1973) in whom the cardiovascular health group with elevated but not high levels of cardiovascular risk factors had the longest life expectancy compared with those with favorable levels of all cardiovascular risk factors. This may be due to the existence of preexisting disease at baseline among this older group of participants. When risk factors were examined separately, the presence of each cardiovascular risk factor individually was associated with a higher cardiovascular morbidity score at each year of age from 65 throughout 90, resulting in a greater cumulative cardiovascular morbidity burden for the group with the risk factor compared with those without ( Figure XII in the online-only Data Supplement).
DISCUSSION
We found that cardiovascular health status, defined by the presence and severity of cardiovascular risk factors, in young adulthood and middle age is associated with the burden of all-cause and cardiovascular morbidity up to 43 years later. Individuals with favorable cardiovascular health at baseline experienced greater longevity and lower all-cause and cardiovascular morbidity throughout older age, resulting in lower morbidity levels at every age from 65 to 90 and ultimately lower cumulative morbidity levels after age 65. These lower morbidity levels translated at the median into more than $5000 fewer dollars per year and almost $18 000 fewer dollars cumulatively being spent by CMS on health care from age 65 on. In general, men experienced a greater benefit in terms of the compression of morbidity resulting from favorable cardiovascular health than women. Individuals in favorable cardiovascular health at younger ages not only live a longer life but live a healthier life and a greater proportion of life free of morbidity.
This study represents some of the first findings that favorable cardiovascular health in middle age is associated with older age at incidence of major morbidity and lower cumulative levels of disability, as well as with healthy, not just greater, longevity. Our findings on the benefits of being in favorable cardiovascular health at younger ages considerably extend the observations of prior research demonstrating a reduction in the incidence of specific CVDs, as well as cancer, 14 depression, 15 and higher cognitive functioning, 16 along with other favorable outcomes. We found that an increasing burden of cardiovascular risk factors was associated with a longer period of life lived with morbidity in a dose-dependent fashion, thus suggesting that any improvements in cardiovascular health will likely translate to reductions in morbidity in older age.
Favorable cardiovascular health in middle age has previously been shown to be associated with increased longevity. 17 The present study extends prior work to pro- Figure 2 . Morbidity-free survival and average time spent with morbidity after age 65 years.
vide an understanding of not only how much longer individuals in favorable cardiovascular health live but also what proportion of that increase is due to an extension of healthy life as opposed to a longer life with more disability.
Beyond disease incidence and mortality, healthcare costs represent an important outcome for public health and policy makers. Among a smaller subset of CHA participants followed up through 2004, favorable cardiovascular health has previously been found to be associated with reduced average annual costs and end-of-life costs. 18, 19 Our findings extend this work to a broader portion of the CHA cohort and demonstrate that lower morbidity scores among those who were in favorable cardiovascular health at baseline translates to lower average annual and cumulative costs up to 40 years later. These findings support prior literature demonstrating lower healthcare costs for individuals in better cardiovascular health in middle age. 20 Less is known about favorable cardiovascular health in middle age and its effects on morbidity and mortality. Since Fries 21 first described the theory of compression of morbidity in 1980, most work has focused on the role of health behaviors. Healthy lifestyle behaviors, that is, exercise, normal weight, and not smoking, have been shown to delay the onset of severe disability and to reduce cumulative disability. 22 Also called healthy aging, the compression of morbidity paradigm suggests that prevention strategies may delay the onset of ill health to a greater degree than they delay date of death, thus resulting in a decreased proportion of life with morbidity.
Until now, whether favorable cardiovascular health results in a compression of morbidity was unclear. A previous study done among the Lifetime Risk Pooling Project found that at younger index ages individuals in favorable cardiovascular health lived up to 14 years longer free of total CVD, although differences in survival after CVD incidence were less dramatic. 23 Our findings provide some of the first information directly testing whether favorable cardiovascular health is associated not only with an extension life and life lived free of morbidity but with an absolute and relative compression of morbidity.
This study has several important strengths, including the use of a large cohort of >25 000 participants, all of whom were examined in person at baseline to measure cardiovascular risk factors objectively; >40 years of follow-up with nearly complete ascertainment of morbidity with CMS Medicare files; and the inclusion of a large proportion of participants who have been followed up to the end of their life, allowing us to estimate cumulative morbidity and end of life costs. Despite these strengths, there are some limitations to consider. We have only a single baseline measure of cardiovascular risk factor profile and are unable to account for changes in risk factor levels or treatments over time. However, the impact of a single measure of cardiovascular health early in middle age has proven to be predictive of long-term outcomes in previous publications from CHA and in other cohorts. 5, [24] [25] [26] If anything, our findings are likely to be a conservative estimate because single estimates of risk factor burden are an underestimation of the strength of the associations as a result of regression dilution bias. We lacked informa- All costs are adjusted for age, sex, race, education, length of follow-up, and death during follow-up. Because of convergence issues, we used 75.5% and 50.5% quantiles in some models.
tion on other measures of socioeconomic status beyond income; however, in theory, all participants had equal access to care given their enrollment in Medicare. We used CMS healthcare use files to identify morbidity, mortality, and cost outcomes and therefore we are able to examine only the 70% to 80% of the cohort enrolled in fee for service. We do not know the use for health maintenance organization users during years of health maintenance organization enrollment; however, risk factor level and morbidity status were not associated with health maintenance organization enrollment (data not shown), and thus, this bias should be nondifferential, leading us to underestimate the strength of our associations. We lack outcomes before age 65 and must use International Classification of Diseases, Ninth Revision codes to determine morbidity. Those codes have been shown to be reliable for the conditions included in the comorbidity scores in this study and have been used for a multitude of clinical investigations. General agreement between comorbidity scores derived from administrative data and chart review has been >85%. 27 Given the reliability of these scores and their well-documented association with mortality, physical functioning, and health-related quality of life, the Gagne comorbidity score serves as a valid and reliable measure of morbidity in older age.
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CONCLUSIONS
We found that individuals in favorable cardiovascular health in early middle age have lower levels of morbidity, both all-cause and cardiovascular, up to 40 years later in life and experience a lower cumulative morbidity burden translating to reduced average annual healthcare costs. Our findings have important implications for prevention. At the individual level, living a longer and healthier life free of major morbidity can provide strong motivation to maintain and improve cardiovascular health across the life span. At the population and healthcare system levels, these findings directly support the need to improve prevention efforts and to target them earlier in life, before the development of adverse risk factor levels (ie, primordial prevention). Our data suggest that the resultant reductions in morbidity could translate to large savings in healthcare spending at the national level.
